The reiteration of a Buy rating and a $41 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards SNDX. This endorsement reaffirms the firm's confidence in Syndax Pharmaceuticals' potential, likely leading to increased investor interest and potentially a positive impact on the stock's short-term price movement.